Last 29.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
ETX On Other Exchanges
Symbol
Exchange
London
Berlin
As of 11:30 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

e-therapeutics plc (ETX) Snapshot

Open
29.00 GBp
Previous Close
29.00 GBp
Day High
29.00 GBp
Day Low
29.00 GBp
52 Week High
05/12/14 - 35.50 GBp
52 Week Low
03/18/14 - 20.00 GBp
Market Cap
76.7M
Average Volume 10 Days
29.4K
EPS TTM
-0.03 GBp
Shares Outstanding
264.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for E-THERAPEUTICS PLC (ETX)

Related News

No related news articles were found.

e-therapeutics plc (ETX) Related Businessweek News

No Related Businessweek News Found

e-therapeutics plc (ETX) Details

e-Therapeutics plc is engaged in the discovery and development of drugs through its proprietary platform in network pharmacology. The company focuses on the discovery of drugs for cancer and degenerative diseases of the nervous system. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; ETS6103, a Phase IIb trial product for depressive disorders; and ETX1153c, an anti-infective drug candidate that is in preclinical stage for the treatment of C. difficile infection. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.

21 Employees
Last Reported Date: 05/30/14
Founded in 2001

e-therapeutics plc (ETX) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: 444.0K GBP
Development Director and Executive Director
Total Annual Compensation: 262.0K GBP
Compensation as of Fiscal Year 2014.

e-therapeutics plc (ETX) Key Developments

e-Therapeutics plc Announces Unaudited Group Earnings Results for the Six Months Ended July 31, 2014

e-Therapeutics plc announced unaudited group earnings results for the six months ended July 31, 2014. For the period, the company reported operating loss of GBP 5,324,000 against GBP 3,090,000 a year ago. Loss before taxation was GBP 5,135,000 against GBP 2,784,000 a year ago. Loss for the period was GBP 4,129,000 against GBP 2,281,000 a year ago. Basic and diluted loss per share was 1.56 pence against 0.93 pence a year ago. Net cash used in operating activities was GBP 6,637,000 against GBP 3,407,000 a year ago. Acquisition of property, plant and equipment was GBP 14,000 against GBP 5,000 a year ago. Acquisition of other intangible assets was GBP 40,000 against GBP 92,000 a year ago.

e-Therapeutics plc. to Report First Half, 2015 Results on Sep 16, 2014

e-Therapeutics plc. announced that they will report first half, 2015 results on Sep 16, 2014

e-Therapeutics plc., H1 2015 Earnings Call, Sep 16, 2014

e-Therapeutics plc., H1 2015 Earnings Call, Sep 16, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETX:LN 29.00 GBp 0.00

ETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETX.
View Industry Companies
 

Industry Analysis

ETX

Industry Average

Valuation ETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.